Crohn’s Disease Market Research Report - Global Forecast till 2032

Crohn’s Disease Market Research Report Information by Type (Ileocolitis, Ileitis, Granulomatous colitis, Gastroduodenal Crohn’s Disease, Jejunoileitis, and Perianal Crohn’s Disease), Treatment (Non-Surgical and Surgical), End User (Hospitals and Clinics, Research Institutes, and Others), and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast till 2032

ID: MRFR/Pharma/1728-HCR | 85 Pages | Author: Kinjoll Dey | March 2024         

1 Introduction

1.1 Definition

TABLE OF CONTENTS

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL CROHN’S DISEASE MARKET, BY TYPE

6.1. Overview

6.2. Ileocolitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Ileitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Granulomatous Colitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Gastroduodenal Crohn’s disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Jejunoileitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.7. Perianal Crohn’s disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027 

7. GLOBAL CROHN’S DISEASE MARKET, BY TYPE

7.1. Overview

7.2. Non-Surgical

7.2.1. Anti-Inflammatory

7.2.1.1. Corticosteroids

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.1.2. Oral 5-Aminosalicylates

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2. Immune System Suppressors

7.2.2.1. Azathioprine

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2.2. Mercaptopurine

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2.3. TNF Inhibitors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2.4. Methotrexate

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2.5. Natalizumab

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2.6. Vedolizumab

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2.7. Ustekinumab

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.3. Antibiotics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Surgical

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL CROHN’S DISEASE MARKET, BY END USER

8.1. Overview

8.2. Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Research Institutes

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL CROHN’S DISEASE MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategies in the Global Crohn’s Disease Market

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of the Number of Developments in the Global Crohn’s Disease Market

10.7. Key developments and Growth Strategies

10.7.1. Product Launch/Service Deployment

10.7.2. Mergers and Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix & Market Ratio

10.8.1. Sales & Operating Income 2020

10.8.2. Major Players R&D Expenditure 2020

10.9. Major Players Capital Market Ratio

11. COMPANY PROFILES

11.1. Johnson & Johnson Services Inc.

11.1.1. Company Overview

11.1.2. Product Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Pfizer Inc.

11.2.1. Company Overview

11.2.2. Product Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. AbbVie Inc

11.3.1. Company Overview

11.3.2. Product Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Allergan

11.4.1. Company Overview

11.4.2. Product Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Amgen, Inc.

11.5.1. Company Overview

11.5.2. Product Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Bayer AG

11.6.1. Company Overview

11.6.2. Product Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Takeda Pharmaceutical Company Limited

11.7.1. Company Overview

11.7.2. Product Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Ferring B.V.

11.8.1. Company Overview

11.8.2. Product Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. UCB S.A.

11.9.1. Company Overview

11.9.2. Product Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Eli Lilly and Company

11.10.1. Company Overview

11.10.2. Product Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Hoffman-La Roche

11.11.1. Company Overview

11.11.2. Product Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Bristol-Myers Squibb

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL CROHN’S DISEASE MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL CROHN’S DISEASE MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL CROHN’S DISEASE MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 11 US: CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 12 US: CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 14 CANADA: CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 15 CANADA: CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: CROHN’S DISEASE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: CROHN’S DISEASE MARKET, BY TREATMENT, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: CROHN’S DISEASE MARKET, BY END USER, 2020-2027 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE OF THE GLOBAL CROHN’S DISEASE MARKET

FIGURE 3 MARKET DYNAMICS OF THE GLOBAL CROHN’S DISEASE MARKET

FIGURE 4 GLOBAL CROHN’S DISEASE MARKET SHARE, BY TYPE, 2020 (%)

FIGURE 5 GLOBAL CROHN’S DISEASE MARKET SHARE, BY TREATMENT, 2020 (%)

FIGURE 6 GLOBAL CROHN’S DISEASE MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL CROHN’S DISEASE MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 AMERICAS: CROHN’S DISEASE MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: CROHN’S DISEASE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: CROHN’S DISEASE MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: CROHN’S DISEASE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: CROHN’S DISEASE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: CROHN’S DISEASE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL CROHN’S DISEASE MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 JOHNSON & JOHNSON SERVICES INC.: KEY FINANCIALS

FIGURE 16 JOHNSON & JOHNSON SERVICES INC.: SEGMENTAL REVENUE

FIGURE 17 JOHNSON & JOHNSON SERVICES INC.: REGIONAL REVENUE

FIGURE 18 PFIZER INC.: KEY FINANCIALS

FIGURE 19 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 20 PFIZER INC.: REGIONAL REVENUE

FIGURE 21 ALLERGAN: KEY FINANCIALS

FIGURE 22 ALLERGAN: SEGMENTAL REVENUE

FIGURE 23 ALLERGAN: REGIONAL REVENUE

FIGURE 24 ABBVIE INC: KEY FINANCIALS

FIGURE 25 ABBVIE INC: SEGMENTAL REVENUE

FIGURE 26 ABBVIE INC: REGIONAL REVENUE

FIGURE 27 BAYER AG: KEY FINANCIALS

FIGURE 28 BAYER AG: SEGMENTAL REVENUE

FIGURE 29 BAYER AG: REGIONAL REVENUE

FIGURE 30 AMGEN, INC.: KEY FINANCIALS

FIGURE 31 AMGEN, INC.: SEGMENTAL REVENUE

FIGURE 32 AMGEN, INC.: REGIONAL REVENUE

FIGURE 33 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY FINANCIALS

FIGURE 34 TAKEDA PHARMACEUTICAL COMPANY LIMITED: SEGMENTAL REVENUE

FIGURE 35 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGIONAL REVENUE

FIGURE 36 UCB S.A.: KEY FINANCIALS

FIGURE 37 UCB S.A: SEGMENTAL REVENUE

FIGURE 38 UCB S.A: REGIONAL REVENUE

FIGURE 39 FERRING B.V.: KEY FINANCIALS

FIGURE 40 FERRING B.V.: SEGMENTAL REVENUE

FIGURE 41 FERRING B.V.: REGIONAL REVENUE

FIGURE 42 ELI LILLY AND COMPANY.: KEY FINANCIALS

FIGURE 43 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 44 ELI LILLY AND COMPANY.: REGIONAL REVENUE

FIGURE 45 HOFFMAN-LA ROCHE: KEY FINANCIALS

FIGURE 46 HOFFMAN-LA ROCHE: SEGMENTAL REVENUE

FIGURE 47 HOFFMAN-LA ROCHE: REGIONAL REVENUE

FIGURE 48 BRISTOL-MYERS SQUIBB: KEY FINANCIALS

FIGURE 49 BRISTOL-MYERS SQUIBB: SEGMENTAL REVENUE

FIGURE 50 BRISTOL-MYERS SQUIBB: REGIONAL REVENUE

 


Market Segmentation Tab


Crohn’s Disease Type Outlook (USD Billion, 2018-2030)



  • Ileocolitis

  • Ileitis

  • Granulomatous colitis

  • Gastroduodenal Crohn’s Disease

  • Jejunoileitis

  • Perianal Crohn’s Disease


Crohn’s Disease Treatment Outlook (USD Billion, 2018-2030)



  • Non-Surgical

  • Surgical


Crohn’s Disease End-User Outlook (USD Billion, 2018-2030)



  • Hospitals and Clinics

  • Research Institutes


Crohn’s Disease Regional Outlook (USD Billion, 2018-2030)




  • North America Outlook (USD Billion, 2018-2030)


    • North America Crohn’s Disease by Type

      • Ileocolitis

      • Ileitis

      • Granulomatous colitis

      • Gastroduodenal Crohn’s Disease

      • Jejunoileitis

      • Perianal Crohn’s Disease




    • North America Crohn’s Disease by Treatment

      • Non-Surgical

      • Surgical




    • North America Crohn’s Disease by End-User

      • Hospitals and Clinics

      • Research Institutes



    • US Outlook (USD Billion, 2018-2030)


    • US Crohn’s Disease by Type

      • Ileocolitis

      • Ileitis

      • Granulomatous colitis

      • Gastroduodenal Crohn’s Disease

      • Jejunoileitis

      • Perianal Crohn’s Disease




    • US Crohn’s Disease by Treatment

      • Non-Surgical

      • Surgical




    • US Crohn’s Disease by End-User

      • Hospitals and Clinics

      • Research Institutes



    • Canada Outlook (USD Billion, 2018-2030)


    • Canada Crohn’s Disease by Type

      • Ileocolitis

      • Ileitis

      • Granulomatous colitis

      • Gastroduodenal Crohn’s Disease

      • Jejunoileitis

      • Perianal Crohn’s Disease




    • Canada Crohn’s Disease by Treatment

      • Non-Surgical

      • Surgical




    • Canada Crohn’s Disease by End-User

      • Hospitals and Clinics

      • Research Institutes




    • Europe Outlook (USD Billion, 2018-2030)


      • Europe Crohn’s Disease by Type

        • Ileocolitis

        • Ileitis

        • Granulomatous colitis

        • Gastroduodenal Crohn’s Disease

        • Jejunoileitis

        • Perianal Crohn’s Disease




      • Europe Crohn’s Disease by Treatment

        • Non-Surgical

        • Surgical




      • Europe Crohn’s Disease by End-User

        • Hospitals and Clinics

        • Research Institutes




      • Germany Outlook (USD Billion, 2018-2030)


      • Germany Crohn’s Disease by Type

        • Ileocolitis

        • Ileitis

        • Granulomatous colitis

        • Gastroduodenal Crohn’s Disease

        • Jejunoileitis

        • Perianal Crohn’s Disease




      • Germany Crohn’s Disease by Treatment

        • Non-Surgical

        • Surgical




      • Germany Crohn’s Disease by End-User

        • Hospitals and Clinics

        • Research Institutes



      • France Outlook (USD Billion, 2018-2030)


      • France Crohn’s Disease by Type

        • Ileocolitis

        • Ileitis

        • Granulomatous colitis

        • Gastroduodenal Crohn’s Disease

        • Jejunoileitis

        • Perianal Crohn’s Disease




      • France Crohn’s Disease by Treatment

        • Non-Surgical

        • Surgical




      • France Crohn’s Disease by End-User

        • Hospitals and Clinics

        • Research Institutes



      • UK Outlook (USD Billion, 2018-2030)


      • UK Crohn’s Disease by Type

        • Ileocolitis

        • Ileitis

        • Granulomatous colitis

        • Gastroduodenal Crohn’s Disease

        • Jejunoileitis

        • Perianal Crohn’s Disease




      • UK Crohn’s Disease by Treatment

        • Non-Surgical

        • Surgical




      • UK Crohn’s Disease by End-User

        • Hospitals and Clinics

        • Research Institutes



      • Italy Outlook (USD Billion, 2018-2030)


      • Italy Crohn’s Disease by Type

        • Ileocolitis

        • Ileitis

        • Granulomatous colitis

        • Gastroduodenal Crohn’s Disease

        • Jejunoileitis

        • Perianal Crohn’s Disease




      • Italy Crohn’s Disease by Treatment

        • Non-Surgical

        • Surgical




      • Italy Crohn’s Disease by End-User

        • Hospitals and Clinics

        • Research Institutes



      • Spain Outlook (USD Billion, 2018-2030)


      • Spain Crohn’s Disease by Type

        • Ileocolitis

        • Ileitis

        • Granulomatous colitis

        • Gastroduodenal Crohn’s Disease

        • Jejunoileitis

        • Perianal Crohn’s Disease




      • Spain Crohn’s Disease by Treatment

        • Non-Surgical

        • Surgical




      • Spain Crohn’s Disease by End-User

        • Hospitals and Clinics

        • Research Institutes



      • Rest Of Europe Outlook (USD Billion, 2018-2030)


      • Rest Of Europe Crohn’s Disease by Type

        • Ileocolitis

        • Ileitis

        • Granulomatous colitis

        • Gastroduodenal Crohn’s Disease

        • Jejunoileitis

        • Perianal Crohn’s Disease




      • Rest Of Europe Crohn’s Disease by Treatment

        • Non-Surgical

        • Surgical




      • Rest Of Europe Crohn’s Disease by End-User

        • Hospitals and Clinics

        • Research Institutes




      • Asia-Pacific Outlook (USD Billion, 2018-2030)


        • Asia-Pacific Crohn’s Disease by Type

          • Ileocolitis

          • Ileitis

          • Granulomatous colitis

          • Gastroduodenal Crohn’s Disease

          • Jejunoileitis

          • Perianal Crohn’s Disease




        • Asia-Pacific Crohn’s Disease by Treatment

          • Non-Surgical

          • Surgical




        • Asia-Pacific Crohn’s Disease by End-User

          • Hospitals and Clinics

          • Research Institutes



        • China Outlook (USD Billion, 2018-2030)


        • China Crohn’s Disease by Type

          • Ileocolitis

          • Ileitis

          • Granulomatous colitis

          • Gastroduodenal Crohn’s Disease

          • Jejunoileitis

          • Perianal Crohn’s Disease




        • China Crohn’s Disease by Treatment

          • Non-Surgical

          • Surgical




        • China Crohn’s Disease by End-User

          • Hospitals and Clinics

          • Research Institutes



        • Japan Outlook (USD Billion, 2018-2030)


        • Japan Crohn’s Disease by Type

          • Ileocolitis

          • Ileitis

          • Granulomatous colitis

          • Gastroduodenal Crohn’s Disease

          • Jejunoileitis

          • Perianal Crohn’s Disease




        • Japan Crohn’s Disease by Treatment

          • Non-Surgical

          • Surgical




        • Japan Crohn’s Disease by End-User

          • Hospitals and Clinics

          • Research Institutes



        • India Outlook (USD Billion, 2018-2030)


        • India Crohn’s Disease by Type

          • Ileocolitis

          • Ileitis

          • Granulomatous colitis

          • Gastroduodenal Crohn’s Disease

          • Jejunoileitis

          • Perianal Crohn’s Disease




        • India Crohn’s Disease by Treatment

          • Non-Surgical

          • Surgical




        • India Crohn’s Disease by End-User

          • Hospitals and Clinics

          • Research Institutes



        • Australia Outlook (USD Billion, 2018-2030)


        • Australia Crohn’s Disease by Type

          • Ileocolitis

          • Ileitis

          • Granulomatous colitis

          • Gastroduodenal Crohn’s Disease

          • Jejunoileitis

          • Perianal Crohn’s Disease




        • Australia Crohn’s Disease by Treatment

          • Non-Surgical

          • Surgical




        • Australia Crohn’s Disease by End-User

          • Hospitals and Clinics

          • Research Institutes



        • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)


        • Rest of Asia-Pacific Crohn’s Disease by Type

          • Ileocolitis

          • Ileitis

          • Granulomatous colitis

          • Gastroduodenal Crohn’s Disease

          • Jejunoileitis

          • Perianal Crohn’s Disease




        • Rest of Asia-Pacific Crohn’s Disease by Treatment

          • Non-Surgical

          • Surgical




        • Rest of Asia-Pacific Crohn’s Disease by End-User

          • Hospitals and Clinics

          • Research Institutes




        • Rest of the World Outlook (USD Billion, 2018-2030)


          • Rest of the World Crohn’s Disease by Type

            • Ileocolitis

            • Ileitis

            • Granulomatous colitis

            • Gastroduodenal Crohn’s Disease

            • Jejunoileitis

            • Perianal Crohn’s Disease




          • Rest of the World Crohn’s Disease by Treatment

            • Non-Surgical

            • Surgical




          • Rest of the World Crohn’s Disease by End-User

            • Hospitals and Clinics

            • Research Institutes



          • Middle East Outlook (USD Billion, 2018-2030)


          • Middle East Crohn’s Disease by Type

            • Ileocolitis

            • Ileitis

            • Granulomatous colitis

            • Gastroduodenal Crohn’s Disease

            • Jejunoileitis

            • Perianal Crohn’s Disease




          • Middle East Crohn’s Disease by Treatment

            • Non-Surgical

            • Surgical




          • Middle East Crohn’s Disease by End-User

            • Hospitals and Clinics

            • Research Institutes



          • Africa Outlook (USD Billion, 2018-2030)


          • Africa Crohn’s Disease by Type

            • Ileocolitis

            • Ileitis

            • Granulomatous colitis

            • Gastroduodenal Crohn’s Disease

            • Jejunoileitis

            • Perianal Crohn’s Disease




          • Africa Crohn’s Disease by Treatment

            • Non-Surgical

            • Surgical




          • Africa Crohn’s Disease by End-User

            • Hospitals and Clinics

            • Research Institutes



          • Latin America Outlook (USD Billion, 2018-2030)


          • Latin America Crohn’s Disease by Type

            • Ileocolitis

            • Ileitis

            • Granulomatous colitis

            • Gastroduodenal Crohn’s Disease

            • Jejunoileitis

            • Perianal Crohn’s Disease




          • Latin America Crohn’s Disease by Treatment

            • Non-Surgical

            • Surgical




          • Latin America Crohn’s Disease by End-User

            • Hospitals and Clinics

            • Research Institutes











Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid